SCYNEXIS, Inc. is a pharmaceutical company that develops antifungal medications to treat and prevent drug-resistant and difficult-to-treat fungal infections. The company's proprietary fungerps platform consists of novel triterpenoid compounds that work as glucan synthase inhibitors; its approved product, ibrexafungerp (marketed as BREXAFEMME), was licensed to GlaxoSmithKline for vulvovaginal candidiasis, while the lead development candidate, SCY-247, is in clinical trials for invasive candidiasis and fungal infection prevention in immunocompromised patients. SCYNEXIS generates revenue through upfront payments, milestone achievements, and royalties from its licensing partners, addressing a significant market need driven by rising antifungal resistance and the limitations of existing treatment options, which are restricted to intravenous-only or azole-based therapies with growing resistance patterns.
| USD millions | FY2025 |
|---|---|
| Revenue | 21 |
| Net Income | -9 |